Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille calmette-guérin–RIVM and mitomycin c in superficial bladder cancer-Reference-Cited by-同舟云学术

Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille calmette-guérin–RIVM and mitomycin c in superficial bladder cancer

Published:1998-09 Issue:3 Volume:52 Page:403-410
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Witjes J.A.,Meijden A.P.M.v.d,Collette L.,Sylvester R.,Debruyne F.M.J.,van Aubel A.,Witjes W.P.J.

Publisher

Elsevier BV

Subject

Urology

Reference22 articles.

1. Complications of bacillus Calmette-Guerin immunotherapy;Lamm;Prog Clin Biol Res,1989

2. Improving the efficacy of BCG immunotherapy by dose reduction;Pagano;Eur Urol,1995

3. Improving the safety of BCG immunotherapy by dose reduction;Eur Urol,1995

4. Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG;Corti Ortiz;Acta Urol Esp,1993

5. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer;Mack;Urology,1995

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis;European Urology Oncology;2024-06

3. Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette–Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis;Frontiers in Oncology;2023-05-12

4. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition);Military Medical Research;2022-08-17

5. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes;World Journal of Urology;2020-11-23